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reductase inhibitors.[2] Serotonin syndrome is a potentially 
life-threatening disorder of excessive serotoninergic activity 
often due to drug interactions.[3] Many other drugs act 
as precipitants or objects, and a number of drugs act as 
both.[2] An overview of selected serious drug interactions 
is given in Table 1.[2]
SERIOUSNESS AND SEVERITY OF DRUG 
INTERACTION
The American Food and Drug Administration define a 
serious adverse event as one when the patient outcome is 
one of the following [4]:
•  Death 
•  Life-threatening
•  Hospitalization (initial or prolonged) 
•  Disability—significant, persistent, or permanent 
change, impairment, damage or disruption in the 
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a great deal of recent attention from the regulatory, 
scientific, and health care communities worldwide.[1] A 
large number of drugs are introduced every year, and 
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physicians to rely on memory alone to avoid potential 
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drug’s absorption, distribution, metabolism, excretion, 
or actual clinical effect. Nonsteroidal anti-inflammatory 
drugs, antibiotics and, in particular, rifampin are common 
precipitant drugs prescribed in primary care practice. 
Drugs with a narrow therapeutic range or low therapeutic 
index are more likely to be the objects for serious drug 
interactions. Object drugs in common use include warfarin, 
fluoroquinolones, antiepileptic drugs, oral contraceptives, 
cisapride, and 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 1: Overview of selected serious drug interactions[2]
Interaction  Potential effect  Time to effect  Recommendations and comments
Warfarin (Coumadin) plus ciprofloxacin 
(Cipro), clarithromycin (Biaxin), erythromycin, 
metronidazole (Flagyl) or trimethoprim-
sulfamethoxazole (Bactrim, Septra)
Increased effect of warfarin Generally within 1 week Select alternative antibiotic
Warfarin plus acetaminophen Increased bleeding, increased INR Any time Use lowest possible acetaminophen 
dosage and monitor INR
Warfarin plus acetylsalicylic acid (aspirin) Increased bleeding, increased INR Any time Limit aspirin dosage to 100 mg per day 
and monitor INR
Warfarin plus NSAID Increased bleeding, increased INR Any time Avoid concomitant use if possible; if 
coadministration is necessary, use a 
cyclooxygenase-2 inhibitor and monitor 
INR
Fluoroquinolone plus divalent/trivalent cations or 
sucralfate (Carafate)
Decreased absorption of 
fluoroquinolone
Any time Space administration by 2–4 h
Carbamazepine (Tegretol) plus cimetidine 
(Tagamet), erythromycin, clarithromycin or 
fluconazole (Diflucan)
Increased carbamazepine levels Generally within 1 week Monitor carbamazepine levels
Phenytoin (Dilantin) plus cimetidine, 
erythromycin, clarithromycin or fluconazole
Increased phenytoin levels Generally within 1 week Monitor phenytoin levels
Phenobarbital plus cimetidine, erythromycin, 
clarithromycin or fluconazole
Increased phenobarbital levels Generally within 1 week Clinical significance has not been 
established. 
Monitor phenobarbital levels
Phenytoin plus rifampin (Rifadin) Decreased phenytoin levels Generally within 1 week Clinical significance has not been 
established. 
Monitor phenytoin levels
Phenobarbital plus rifampin Decreased phenobarbital levels Generally within 1 week Monitor phenobarbital levels
Carbamazepine plus rifampin Decreased carbamazepine levels Generally within 1 week Clinical significance has not been 
established. 
Monitor carbamazepine levels
Lithium plus NSAID or diuretic Increased lithium levels  Any time Decrease lithium dosage by 50% and 
monitor lithium levels
Oral contraceptive pills plus rifampin Decreased effectiveness of oral 
contraception
Any time Avoid if possible. If combination 
therapy is necessary, have the patient 
take an oral contraceptive pill with 
a higher estrogen content (>35 µg 
of ethinyl estradiol) or recommend 
alternative method of contraception
Oral contraceptive pills plus antibiotics Decreased effectiveness of oral 
contraception
Any time Avoid if possible. If combination 
therapy is necessary, recommend use of 
alternative contraceptive method during 
cycle
Oral contraceptive pills plus troglitazone 
(Rezulin)
Decreased effectiveness of oral 
contraception
Any time Have the patient take an oral 
contraceptive pill with a higher estrogen 
content or recommend alternative 
method of contraception
Cisapride (Propulsid) plus erythromycin, 
clarithromycin, fluconazole, itraconazole 
(Sporanox), ketoconazole (Nizoral), nefazodone 
(Serzone), indinavir (Crixivan) or ritonavir 
(Norvir)
Prolongation of QT interval along 
with arrhythmias secondary to 
inhibited cisapride metabolism
Generally within 1 week Avoid. Consider whether 
metoclopromide (Reglan) therapy is 
appropriate for the patient
Cisapride plus class IA or class III antiarrhythmic 
agents, tricyclic antidepressants or phenothiazine
Prolongation of QT interval along 
with arrhythmias
Any time Avoid. Consider whether 
metoclopromide therapy is appropriate 
for the patient
Sildenafil (Viagra) plus nitrates Dramatic hypotension Soon after taking sildenafil Absolute contraindication
Sildenafil plus cimetidine, erythromycin, 
itraconazole or ketoconazole
Increased sildenafil levels Any time Initiate sildenafil at a 25-mg dose
HMG-CoA reductase inhibitor plus niacin, 
gemfibrozil (Lopid), erythromycin or itraconazole
Possible rhabdomyolysis Any time  Avoid if possible. If combination 
therapy is necessary, monitor the patient 
for toxicity
Lovastatin (Mevacor) plus warfarin Increased effect of warfarin Any time Monitor INR
SSRI plus tricyclic antidepressant Increased tricyclic antidepressant 
level
Any time Monitor for anticholinergic excess 
and consider lower dosage of tricyclic 
antidepressant
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patient’s body function/structure, physical activities, 
or quality of life. 
•  Congenital anomaly 
•  Requires intervention to prevent permanent impairment 
or damage 
Severity is a point on an arbitrary scale of intensity of 
the adverse event in question. The terms “severe” and 
“serious” when applied to adverse events are technically 
very different. They are easily confused but cannot be used 
interchangeably, require care in usage. A headache is severe, 
if it causes intense pain. There are scales such as “Visual 
Analog Scale” that helps us assess the severity. On the other 
hand, a headache can hardly ever be serious, unless it also 
satisfies the criteria for seriousness listed above.
MECHANISMS
As research better explains the biochemistry of drug use, 
fewer ADRs (adverse drug reactions) are Type B and more 
are Type A. Common mechanisms are:
Abnormal pharmacokinetics due to 
•  genetic factors
•  comorbid disease states 
Synergistic effects between either 
•  a drug and a disease 
•  two drugs 
Abnormal pharmacokinetics
Comorbid disease states
Various diseases, especially those that cause renal or hepatic 
insufficiency, may alter drug metabolism. Resources are 
available that report changes in a drug’s metabolism due 
to disease states.[5] 
Genetic factors
Abnormal drug metabolism may be due to inherited factors 
of either Phase I oxidation or Phase II conjugation.[6,7] 
Pharmacogenomics is the study of the inherited basis for 
abnormal drug reactions.
Phase I reactions
Inheriting abnormal alleles of cytochrome P450 can alter 
drug metabolism. Tables are available to check for drug 
interactions due to P450 interactions.[8,9] 
Inheriting  abnormal  butyrylcholinesterase 
(pseudocholinesterase) may affect metabolism of drugs 
such as succinylcholine.[10] 
Phase II reactions
Inheriting abnormal N-acetyltransferase which conjugated 
some drugs to facilitate excretion may affect the 
metabolism of drugs such as isoniazid, hydralazine, 
and procainamide.  [9,10] Inheriting abnormal thiopurine 
S-methyltransferase may affect the metabolism of the 
thiopurine drugs mercaptopurine and azathioprine.[9]
Interactions with other drugs
The risk of drug interactions is increased with polypharmacy.
Protein binding
These interactions are usually transient and mild until a 
new steady state is achieved. These are mainly for drugs 
without much first-pass liver metabolism. The principal 
plasma proteins for drug binding are [11]:
•  albumin 
•  α1-acid glycoprotein 
•  lipoproteins
Some drug interactions with warfarin are due to changes 
in protein binding.[11]
Table 1: Contd....
SSRI plus selegiline (Eldepryl) or nonselective 
monoamine oxidase inhibitor
Hypertensive crisis Soon after initiation Avoid
SSRI plus tramadol (Ultram) Increased potential for seizures; 
serotonin syndrome
Any time Monitor the patient for signs and 
symptoms of serotonin syndrome
SSRI plus St. John’s wort Serotonin syndrome Any time Avoid
SSRI plus naratriptan (Amerge), rizatriptan 
(Mazalt), sumatriptan (Imitrex) or zolmitriptan 
(Zomig)
Serotonin syndrome Possibly after initial dose Avoid if possible. If combination 
therapy is necessary, monitor the patient 
for signs and symptoms of serotonin 
syndrome
INR, International Normalized Ratio; NSAID, nonsteroidal anti-inflammatory drug; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor; SSRI, selective 
serotonin reuptake inhibitor
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Cytochrome P450
Patients have abnormal metabolism by cytochrome P450 
due to either inheriting abnormal alleles or drug interactions. 
Tables are available to check for drug interactions due to 
P450 interactions.[8]
Synergistic effect
An example of synergism is two drugs that both prolong 
the QT interval.
MANAGEMENT OF DRUG INTERACTION
T he  r ole  of   phar macogenetics  and 
pharmacogenomics[12]
An individual’s genetic makeup can alter their response 
to a drug. Genetics affect pharmacokinetics and 
pharmacodynamics. Unrecognized mutations can be 
associated with ADRs or can affect the magnitude of a 
drug interaction. A common example is the metabolism 
of ethanol. There are ethnic differences in the metabolism 
of ethanol by alcohol dehydrogenase. People of Chinese 
descent have a higher incidence of atypical alcohol 
dehydrogenase and therefore become flushed and dizzy 
when they consume alcohol. Their capacity for consuming 
alcohol is lower than that for other populations.
To apply pharmacogenetics and pharmacogenomics to the 
management of drug interactions, it is important to know 
the difference between the two terms. Pharmacogenetics 
applies to inherited traits and genetic polymorphisms. 
Polymorphism refers to stable allelic variations found in 
the population (occurring at a frequency >1%) that result 
in altered protein activity. Pharmacogenomics applies to 
the entire spectrum of genes. With pharmacogenetics, the 
focus is on metabolizing enzymes and transporters, whereas 
with pharmacogenomics, the focus is on individualized 
drug and dosage for a specific disease.
The role of pharmacist in management of drug 
interaction 
The pharmacist, along with the prescriber has a duty to 
ensure that patients are aware of the risk of side effects 
and a suitable course of action should they occur. With 
their detailed knowledge of medicine, pharmacists have 
the ability to relate unexpected symptoms experienced by 
patients to possible adverse effects of their drug therapy. 
The practice in clinical pharmacy also ensures that ADRs 
are minimized by avoiding drugs with potential side effects 
in susceptible patients. Thus, pharmacist has a major role 
to play in relation to prevention, detection, and reporting 
ADRs.[13] 
Management options of drug interaction include
Avoiding the combination entirely: For some drug interactions, 
the risk always outweighs the risk, and the combination 
should be avoided. Because drug classes are usually 
heterogeneous with regard to drug interactions (as 
described above), one can often select a no interacting 
alternative for either the object drug or the precipitant 
drug.[14]
Adjusting the dose of  the object drug: Sometimes, it is possible 
to give the two interacting drugs safely as long as the dose 
of the object drug is adjusted.
Spacing dosing times to avoid the interaction: For some drug 
interactions involving binding in the gastrointestinal tract, 
to avoid the interaction one can give the object drug at 
least 2 h before or 4 h after the precipitant drug. In this 
way, the object drug can be absorbed into the circulation 
before the precipitant drug appears.
Monitoring for early detection: In some cases, when it is 
necessary to administer interacting drug combinations, 
the interaction can be managed through close laboratory 
or clinical monitoring for the evidence of the interaction. 
In this way, the appropriate dosage changes can be made, 
or the drugs discontinued if necessary.
Provide information on patient risk factors that increases the chance of  
an adverse outcome: It is clear from the clinical experience of 
physicians and pharmacists as well as published studies that 
most patients who take interacting drug combinations do 
not manifest adverse consequences.[15] Substantial evidence 
from both the clinical experience of physicians and 
pharmacists as well as published studies suggest that the 
risk of statin-induced myopathy increases with increasing 
serum concentrations of the statin. Accordingly, it has been 
recommended that simvastatin should not exceed 20 mg 
daily in patients receiving verapamil concurrently.[16] 
Improve computerized screening systems: It is clear that 
computerized drug interaction screening systems have not 
been as successful as one hoped.[14,17]
Excessive number of  drug interactions on the systems: Many 
pharmacists find that computerized drug interaction 
screening systems detect a large number of DDIs of 
questionable clinical significance.
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Drug class differences not handled correctly: Almost all drug classes 
interact heterogeneously, because individual members 
of a drug class are often not metabolized by the same 
cytochrome P450 isozymes or ABC (ATP-binding cassette) 
transporters as other members of the class. The statins 
are a good example, because simvastatin and lovastatin 
are extensively metabolized by CYP3A4, atorvastatin 
is moderately metabolized by CYP3A4, fluvastatin is 
metabolized by CYP2C9, and pravastatin and rosuvastatin 
are not metabolized by cytochrome P450 isozymes.[18] Thus, 
combining all members of this drug class together is rarely 
justified when considering drug interactions. Nonetheless, 
it is common for reviews and computer systems to include 
all statins together as interacting with CYP3A4 inhibitors, 
even though the risk is primarily limited to lovastatin, 
simvastatin, and to a lesser extent, atorvastatin.[19] 
CURRENT INDIAN SCENARIO OF DRUG 
INTERACTIONS AND ITS MANAGEMENT 
The prescribing information for most drugs contains 
a list of potential drug interactions. Many of the listed 
interactions may be rare, minor, or only occur under specific 
conditions and may not be important. Drug interactions 
that cause important changes in the action of a drug are 
of the greatest concern. 
Drug interactions are complex and chiefly unpredictable. A 
known interaction may not occur in every individual. This 
can be explained because there are several factors that affect 
the likelihood that a known interaction will occur. These 
factors include differences among individuals in their;[20,21]
•  genes, 
•  physiology, 
•  age, 
•  lifestyle (diet, exercise), 
•  underlying diseases, 
•  drug doses, 
•  the duration of combined therapy, and 
•  the relative time of administration of the two 
substances (Sometimes, interactions can be avoided if 
two drugs are taken at different times). 
Nevertheless, important drug interactions occur frequently 
and they add millions of dollars to the cost of health care. 
Moreover, many drugs have been withdrawn from the 
market because of their potential to interact with other 
drugs and cause serious health care problems. 
Management[22]
•  Before starting any new prescription drug or over-the-
counter drug, talk to your primary health care provider 
or pharmacist. Make sure that they are aware of any 
vitamins or supplements that you take. 
•  Make sure to read the patient information handout 
given to you at the pharmacy. If you are not given an 
information sheet, ask your pharmacist for one. 
•  Check the labels of your medications for any warnings 
and look for the “Drug Interaction Precaution.” Read 
these warnings carefully. 
•  Make a list of all your prescription medications and 
over-the-counter products, including drugs, vitamins, 
and supplements. Review this list with all health care 
providers and your pharmacist. 
•  If possible, use one pharmacy for all your prescription 
medications and over-the-counter products. This way 
your pharmacist has a record of all your prescription 
drugs and can advise you about drug interactions and 
side effects. 
This brief overview of drug interactions does not cover 
every possible scenario. Individuals should not be afraid 
to use their drugs because of the potential for drug 
interactions. Rather, they should use the information that is 
available to them to minimize the risk of such interactions 
and to improve the success of their therapy.
SOME GUIDELINES FOR COMMUNITY 
PHARMACIST[20,21]
Performing or obtaining necessary assessments of the 
patient’s health status is as follows:
•  Formulating a medication treatment plan: selecting, 
initiating, modifying, or administering medication 
therapy.
•  Monitoring and evaluating the patient’s response to 
therapy, including safety and effectiveness.
•  Performing a comprehensive medication review to 
identify, resolve, and prevent medication-related 
problems, including adverse drug events.
•  Documenting the care delivered and communicating 
essential information to the patient’s other primary 
care providers.
•  Providing verbal education and training designed to 
enhance patient understanding and appropriate use of 
his or her medications.
•  Providing information, support services, and resources 
designed to enhance patient adherence with his or her 
therapy.
•  Coordinating and integrating medication therapy 
management services within the broader health care-
management services being provided to the patient.
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•  Give health care practitioners a complete list of all of 
the drugs that you are using or have used within the 
last few weeks. This should include over-the-counter 
medications, vitamins, food supplements, and herbal 
remedies. 
•  Inform health care practitioners when medications are 
added or discontinued. 
•  Inform health care practitioners about changes in 
lifestyle (for example, exercise, diet, alcohol intake). 
•  Ask your health care practitioners about the most 
serious or frequent drug interactions with the 
medications that you are taking. 
•  Since the frequency of drug interactions increases with 
the number of medications, work with your health care 
practitioners to eliminate unnecessary medications. 
CONCLUSION
The past several years have seen major advances in our 
understanding of DDIs, particularly in the area of the 
molecular mechanisms by which drug interact. However, 
our ability to appropriately apply this information to 
specific patients has lagged far behind. Pharmacists must 
take responsibility for monitoring for drug interactions 
and notifying the physician and patient about potential 
problems.
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